Gold prices steady ahead of Fed decision, Trump’s tariff deadline
SAN FRANCISCO - Polarean Imaging plc (AIM:POLX), a company specializing in advanced Magnetic Resonance Imaging (MRI) technology, is showcasing its Xenon (NASDAQ:XENE) MRI platform at the American Thoracic Society’s (ATS) 2025 International Conference in San Francisco, California. The event, which spans from May 16-21, features Polarean’s technology in over 30 studies presented by leading clinical sites.
The studies at the ATS 2025 International Conference cover a broad range of respiratory conditions, including asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, pulmonary arterial hypertension, radiation-induced lung injury, and post-transplant lung monitoring. This diverse application of Xenon MRI underlines its potential as a versatile tool in both clinical care and pharmaceutical research.
Polarean’s technology was also highlighted at the Respiratory Innovation Summit (RIS), a precursor to the ATS conference, which emphasizes cross-sector dialogue among innovators, investors, clinicians, and patient advocacy groups. The company’s presence at these events signifies its growing role in the future of respiratory care.
Christopher von Jako, PhD, CEO of Polarean, expressed the company’s honor in being featured at RIS and emphasized the importance of these conferences for fostering partnerships and showcasing clinical evidence supporting Xenon MRI. He stated that the technology is not only gaining recognition but is also shaping the future of functional lung imaging and respiratory care.
The presentations at the ATS conference aim to reinforce the sustained momentum behind Xenon MRI as a powerful technology in pulmonary medicine. Polarean’s representatives will be available throughout the events to engage with various stakeholders in the field.
The company’s participation in these conferences is part of its ongoing efforts to advance the understanding and application of functional lung imaging, with the aim of personalizing treatment and accelerating advancements in respiratory medicine. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.